OncoMatch/Clinical Trials/NCT06547840
A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
Is NCT06547840 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies MOv18 IgE for advanced ovarian cancer.
Treatment: MOv18 IgE — EPS101-10-02 is a Phase Ib open label, multicentre clinical trial comprising of a Dose Escalation phase (Part 1) followed by a Dose Expansion phase (Part 2) of MOv18 IgE in patients with folate receptor alpha-expressing (5% or higher) platinum resistant ovarian cancer The dose escalation part of the study will primarily assess the safety and tolerability of MOv18 IgE in ascending dose cohorts, until the determination of the maximum tolerated dose (MTD) or maximum administered dose (MAD). Part 2 (dose expansion) will further assess the safety, tolerability and anti-tumour activity of MOv18 IgE.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Triple-Negative Breast Cancer
Breast Carcinoma
Endometrial Cancer
Biomarker criteria
Required: FOLR1 expression (≥5% of tumour cells by IHC (BN3.2 or FOLR1 antibody))
Tumour tissue expressing FRα on at least 5% of tumour cells, as determined by immunohistochemistry using either (i) the BN3.2 antibody (Leica Biosystems) or (ii) the FOLR1 (FOLR1-2.1) antibody (Ventana)
Required: HER2 (ERBB2) wild-type (IHC 0 or 1+ or negative ISH)
HER2-negative in situ hybridization test or an immunohistochemistry (IHC) status of 0 or 1+
Required: ESR1 wild-type (<10% by IHC)
ER and PgR expressions <10% as determined locally by IHC assay as per most recent ASCO/CAP guidelines
Required: PR (PGR) wild-type (<10% by IHC)
ER and PgR expressions <10% as determined locally by IHC assay as per most recent ASCO/CAP guidelines
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Lab requirements
Blood counts
ANC ≥1.5 × 10^9/L (>1,500/mm3) without G-CSF/GM-CSF; Platelets ≥100 × 10^9/L (>100,000/mm3); Haemoglobin >9 g/dL (stable for at least 1 week post-transfusion); Lymphocyte count ≥1000 cells/mm3 (1.0x10^9/L); Adequate coagulation: PT ≤1.5 × ULN or INR <1.5 and aPTT ≤1.5 × ULN (not required for patients on stable anticoagulant).
Kidney function
eGFR or calculated creatinine clearance >45 mL/min (Cockcroft Gault equation), or ≥60 mL/min for a patient with creatinine levels >1.5 × institutional ULN.
Liver function
Serum total bilirubin ≤1.5 × ULN or direct bilirubin ≤ ULN for a patient with total bilirubin levels >1.5 × ULN; AST (SGOT) and ALT (SGPT) ≤2.5 × ULN or ≤5 × ULN for a patient with liver metastases; Albumin ≥3.0 g/dL.
Adequate haematological function... Adequate renal function... Adequate hepatic function...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06547840 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require FOLR1?
Yes, FOLR1 expression is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 wild-type is a required biomarker for enrollment.
Does this trial require ESR1?
Yes, ESR1 wild-type is a required biomarker for enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify